Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix.

NCT03256916 is registered in ClinicalTrials.gov with Tata Memorial Hospital as lead sponsor.

NCT NCT03256916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03256916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix.
Lead sponsor
Tata Memorial Hospital
Phase
Phase 3
Overall status
Completed
Start date
January 16, 2018
Completion date
May 28, 2024
Enrollment
348 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma cervix,stage iii